Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$228.03
+0.1%		$248.52
$186.05
▼
$282.15
$14.21B0.38871,766 shs783,210 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$66.14
-1.7%		$75.78
$52.75
▼
$93.42
$13.15B0.972.94 million shs2.17 million shs
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$88.04
-0.2%		$104.46
$32.22
▼
$117.88
$4.83B1.35890,098 shs597,417 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$58.85
+0.8%		$55.97
$33.76
▼
$61.14
$14.47B0.472.04 million shs2.58 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+0.07%-0.88%-15.72%-14.59%+11.75%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-1.65%-0.71%-11.62%-15.11%+25.12%
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-0.19%+0.24%-18.56%-8.06%+151.97%
Exelixis, Inc. stock logo
EXEL
Exelixis
+0.79%+0.82%-0.27%+3.10%+46.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$228.03
+0.1%		$248.52
$186.05
▼
$282.15
$14.21B0.38871,766 shs783,210 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$66.14
-1.7%		$75.78
$52.75
▼
$93.42
$13.15B0.972.94 million shs2.17 million shs
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$88.04
-0.2%		$104.46
$32.22
▼
$117.88
$4.83B1.35890,098 shs597,417 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$58.85
+0.8%		$55.97
$33.76
▼
$61.14
$14.47B0.472.04 million shs2.58 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+0.07%-0.88%-15.72%-14.59%+11.75%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-1.65%-0.71%-11.62%-15.11%+25.12%
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-0.19%+0.24%-18.56%-8.06%+151.97%
Exelixis, Inc. stock logo
EXEL
Exelixis
+0.79%+0.82%-0.27%+3.10%+46.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$310.7536.28% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$102.6155.14% Upside
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
2.93
Moderate Buy$129.8347.47% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.35
Hold$50.29-14.55% Downside

Current Analyst Ratings Breakdown

Latest DNTH, EXEL, ASND, and BBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/5/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
10/5/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
10/5/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/25/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D) ➝ Sell (D-)
9/25/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$300.00
9/16/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$344.00
9/15/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Outperform$287.00
9/14/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
9/11/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/11/2026
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$135.00
9/10/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Sell (D)
(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M17.46N/AN/A($2.97) per share-76.78
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M25.75N/AN/A($10.77) per share-6.14
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$2.04M2,365.00N/AN/A$11.41 per share7.72
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.32B6.28$3.05 per share19.29$8.06 per share7.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8917.6925.54N/A70.99%32.54%7.71%11/11/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.57N/AN/AN/A-97.03%N/A-61.19%10/28/2026 (Estimated)
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$162.34M-$4.15N/AN/AN/A-10,096.95%-22.53%-21.55%11/5/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1818.5115.821.7435.33%42.17%31.76%11/3/2026 (Estimated)

Latest DNTH, EXEL, ASND, and BBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/28/2026Q3 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.6132N/AN/AN/A$269.01 millionN/A
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
8/4/2026Q2 2026
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$0.8463-$0.90-$0.0537-$0.90$0.30 million$0.76 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.17
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
N/A
26.10
26.10
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
47.53%
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
3.02%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
839195.49 million167.67 millionOptionable
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
9254.80 million53.14 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable

Recent News About These Companies

Exelixis (NASDAQ:EXEL) Sets New 1-Year High - Here's Why
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31078663
Exelixis stock hits all-time high at 59.73 USD
October 1, 2026  |  au.investing.comhttps://au.investing.com/news/stock-market-news/exelixis-stock-hits-alltime-high-at-5973-usd-93CH-4666703
Exelixis Shares Rising on CABOMETYX Revenue
September 30, 2026  |  fxempire.comF
Exelixis (NASDAQ:EXEL) Reaches New 52-Week High - Should You Buy?
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-exelixis-nasdaq-exel-reaches-new-52-week-high-should-you-buy-2026-09-30/
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?
September 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2998089/exelixis-exel-is-a-top-ranked-growth-stock-should-you-buy?cid=cs-stocknewsapi-ft-fundamental_analysis|zacks_education_growth_score-2998089
Exelixis, Inc. $EXEL Shares Bought by Envestnet Asset Management Inc.
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-exelixis-inc-exel-shares-bought-by-envestnet-asset-management-inc-2026-09-28/
Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies
September 24, 2026  |  gut.bmj.comG
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
September 24, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2995381/could-zanzalintinib-s-fda-delay-affect-exelixis-growth-plans?cid=cs-stocknewsapi-ft-analyst_blog|rank_focused-2995381
State Street Corp Has $542.47 Million Holdings in Exelixis, Inc. $EXEL
September 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-state-street-corp-has-54247-million-holdings-in-exelixis-inc-exel-2026-09-24/
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
September 23, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2994430/here-s-why-exelixis-exel-is-a-strong-momentum-stock?cid=cs-stocknewsapi-ft-fundamental_analysis|zacks_education_momentum_score-2994430
Exelixis, Inc. (NASDAQ:EXEL) Given Average Rating of "Hold" by Brokerages
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-exelixis-inc-nasdaq-exel-given-average-rating-of-hold-by-brokerages-2026-09-22/
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Biotech with Strong Revenue Growth and Strategic Collaborations
September 21, 2026  |  directorstalkinterviews.comhttps://www.directorstalkinterviews.com/exelixis-inc-exel-stock-analysis-navigating-biotech-with-strong-revenue-growth-and-strategic-collaborations/4121263231
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
September 21, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2992926/why-exelixis-exel-is-a-top-value-stock-for-the-long-term?cid=cs-stocknewsapi-ft-fundamental_analysis|zacks_education_value_score-2992926
Bank of America Corp DE Boosts Stake in Exelixis, Inc. $EXEL
September 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-boosts-stake-in-exelixis-inc-exel-2026-09-19/
Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-exelixis-eyes-oncology-deals-readies-zanzalintinib-launch-as-cabozantinib-tops-3b-2026-09-17/
Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?
September 17, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/exelixis-exel-faces-a-three-month-zanzalintinib-review-extension-can-the-data-support-approval-1837507/
Analysts Offer Insights on NA Companies: Exelixis (EXEL) and Resolution Minerals Ltd. Sponsored ADR (RML)
September 15, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/EXEL/pressreleases/4615020/analysts-offer-insights-on-na-companies-exelixis-exel-and-resolution-minerals-ltd-sponsored-adr-rml/
Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946603-exelixis-inc-exel-presents-at-morgan-stanley-24th-annual-global-healthcare-conference
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-exelixis-eyes-zanza-launch-as-cabometyx-growth-faces-net-ramp-hurdle-2026-09-15/
Exelixis: Why The 3-Month Delay Is More Negative Than It May Seem (Downgrade)
September 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946006-exelixis-why-the-3-month-delay-is-more-negative-than-it-may-seem-downgrade
Exelixis Rated Hold as Zanzalintinib CRC Outlook Remains Mixed; $54 Price Target Reaffirmed
September 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/exelixis-rated-hold-as-zanzalintinib-crc-outlook-remains-mixed-54-price-target-reaffirmed-ratings-news?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$228.03 +0.16 (+0.07%)
Closing price 10/5/2026 04:00 PM Eastern
Extended Trading
$228.07 +0.04 (+0.02%)
As of 10/5/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$66.14 -1.11 (-1.65%)
Closing price 10/5/2026 04:00 PM Eastern
Extended Trading
$68.07 +1.93 (+2.92%)
As of 10/5/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Dianthus Therapeutics stock logo

Dianthus Therapeutics NASDAQ:DNTH

$88.04 -0.17 (-0.19%)
Closing price 10/5/2026 04:00 PM Eastern
Extended Trading
$85.28 -2.76 (-3.13%)
As of 10/5/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$58.85 +0.46 (+0.79%)
Closing price 10/5/2026 04:00 PM Eastern
Extended Trading
$58.84 -0.01 (-0.02%)
As of 10/5/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas